Case Study: Branding

KBI Biopharma Sub-Brand Modality Treatment

KBI Biopharma serves four major modalities, or business units: Mammalian, Microbial, Cell Therapy, and Analytical. The company had a high-level visual identity with a logo, primary colors, and minimal corporate photography but lacked corporate typography, patterns, layout, icons, and illustrations, as well as sub-branding and messaging for individual business units.

In late 2022, early 2023, I lead the creative team to deliver a more cohesive visual identity, with a launch date coinciding with BIO International, a large biotech tradeshow. In mid-2023, the company announced operational consolidation with their sister company, Selexis SA, as well as a the launch of PUREplatform™ in their Microbial business unit. These announcements informed the launch of the sub-brand treatment, brand architecture, and brand guidelines, as well as a website redesign.

The visual identity was solidified with Konnect font as the corporate typography and a hexagonal pattern used in various ways across platforms. Additionally, videography, custom layouts, modality specific icons, and custom illustrations, tied the company’s visual identity together for launch. This currently spans across all global platforms, including the company’s website, digital advertising, print assets, and major trade show booth design, all seen below.